recurrent

Betamethasone valerate (Luxiq) is a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions.

BIX-01294 trihydrochloride is an inhibitor of G9a histone methyltransferase.In a cell-free assay, the IC50=2.7 μM for G9a histone methyltransferase.

BIX-01294 is an G9a Histone Methyltransferase inhibitor(IC50 : 1.9 μM).

Borofalan-10B (L-4-Boronophenylalanine) echibits antineoplastic effects. Borofalan can be used in studies on recurrent or locally advanced head and neck cancer.

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

Opicinumab (BIIB033) is a novel monoclonal antibody against LINGO-1 that may be used to prevent and delay acute optic neuritis and recurrent multiple sclerosis.

Silperisone HCl (RGH-5002) blocks sodium and calcium channels in cells, decreases excitability and contractility of muscle cells, reduces peripheral tone, and acts as a muscle relaxant and peripheral vasodilator. Silperisone HCl is used to treat recurrent painful myoclonus due to spinal cord injury, abnormal hypertonia due to cerebrovascular disease, dystonia symptoms, cone tension syndrome, multiple sclerosis myospasm and myelitis. silperisone is a sodium channel protein type 2 alpha channel blocker. silperisone is an organosilicon similar to tolperisone, an organosilicon compound with centrally acting muscle relaxant properties.

Pyrrole-2-carboxylic acid (Minaline) was first identified as a degradation product of sialic acids, then as a derivative of the oxidation of the D-hydroxyproline isomers by mammalian D-amino acid oxidase. The latter relationship results from the lability of the direct oxidation product, A'-pyrroline-4-hydroxy-2-carboxylic acid, which loses water spontaneously to form the pyrrole. A similar reaction is catalyzed by the more specific allohydroxy-D-proline oxidase of Pseudomonas. In whole animal observations, pyrrole-2-carboxylate (PCA) ' was identified in rat or human urine after administration of the D-isomers of hydroxyproline, a finding ascribable to the action of D-amino acid oxidase. Urinary excretion of N-(pyrrole-2-carboxyl) glycine has been reported in a 5-year-old affected with type II hyperprolinemia; The child has mild developmental delay, recurrent seizures of the grand mal type and EEG alterations.

2-Methylsuccinic acid (Pyrotartaric Acid) is a normal metabolite found in human fluids. Increased urinary levels of 2-Methylsuccinic acid (Pyrotartaric Acid) (together with ethylmalonic acid) are the main biochemical measurable features in ethylmalonic encephalopathy, a rare metabolic disorder with an autosomal recessive mode of inheritance that is clinically characterized by neuromotor delay, hyperlactic acidemia, recurrent petechiae, orthostatic acrocyanosis, and chronic diarrhea.

Hydrocortisone sodium succinate (Hydrocortisone sodium succinate) , as a glucocorticoid, is an orally active steroidal anti-inflammatory agent (SAID) with both anti-inflammatory and immunomodulatory functions. It inhibits the biological activities of IL-6 and IL-3, with IC50 values of 6.7 μM and 21.4 μM, respectively. Hydrocortisone sodium succinate is also used in research related to ulcerative colitis (UC) and recurrent aphthous ulcers.

1-Docosanol (Behenic alcohol) is a saturated 22-carbon aliphatic alcohol with antiviral activity. 1-Docosanol has a distinct mechanism of action and inhibits fusion between the plasma membrane and the herpes simplex virus envelope, thereby preventing viral entry into cells and subsequent viral activity and replication. 1-Docosanol is used topically in the treatment of recurrent herpes simplex labialis episodes and relieves associated pain and may help heal sores faster.

Golotimod (SCV 07) is an antimicrobial dipeptide with immunomodulatory activity that significantly improves the efficacy of anti-tuberculosis therapy, induces thymic and splenic cell proliferation, modulates macrophage function, and inhibits STAT3 signaling.Golotimod has been used in the study of recurrent genital Herpes Simplex Virus 2 (HSV-2) infection and oral mucositis.

Golotimod TFA (SCV 07 TFA) is a dipeptide exhibiting immunomodulatory and antibacterial activity. It reduces recurrent lesions caused by HSV-2, alleviates radiation-induced oral mucositis, and inhibits the homodimerisation of STAT3 molecules in the cytoplasm.

MGB-BP-3 is a synthetic antibiotic with bactericidal activity that inhibits bacterial DNA replication and can be used to study recurrent C. difficile infections.

Betamethasone 17-benzoate, a representative steroid, is used in the treatment of recurrent aphthous ulcers (RAU).

EC1169 is a targeted tubulysin conjugate that utilizes EC1167 as its linker. This compound shows promise in the treatment of recurrent metastatic, castration-resistant prostate cancer (MCRPC)[1].

GSK2636771, an effective, specific, orally bioavailable, PI3Kβ inhibitor, has been used in cancer, lymphoma, solid neoplasm, recurrent solid neoplasm, and advanced malignant neoplasm.

KC-764 is an orally active reversible cyclooxygenase inhibitor with relative selectivity for platelet cyclooxygenase. It inhibits the production of thromboxane A2 (TXA2) in platelets and platelet aggregation, with IC50 values of 0.23 μM and 26 nM, respectively. KC-764 is applicable in research on antiplatelet therapy and the prevention of recurrent high-risk ischemic stroke.

Dacetuzumab (SGN 40) is a humanized anti-CD40 monoclonal antibody with antitumor activity that induces the expression of the pro-apoptotic proteins TAp63 and Fas, and can be used to study recurrent diffuse large B-cell lymphomas.

Imalumab (BAX69) is a recombinant humanised monoclonal antibody that targets and inhibits MIF (macrophage inhibitory factor), exhibiting anticancer activity. It is applicable for advanced solid tumours such as ovarian cancer and non-small cell lung cancer.

Bectumomab (IMMU-LL 2), a humanized IgG2a monoclonal antibody (mAb) against human CD22 (antigen), serves as an anti-lymphoma agent. It is utilized in imaging procedures when combined with technetium 99 (Tc99m LL2 Fab), and employed in evaluating the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL). Additionally, Bectumomab is used to examine targeting efficacy prior to radioimmunotherapy (RIT) [1].

Tagitanlimab (HBM-9167; KL-A167) is a humanized monoclonal antibody targeting PD-L1 that selectively blocks PD-L1-PD-1 interactions. It can be used to study recurrent or metastatic nasopharyngeal carcinoma (NPC).

Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1 with antitumor activity, used in studies of recurrent or metastatic cervical cancer.

Mezagitamab (TAK-079) is a fully humanized IgG1λ monoclonal antibody against CD38 with high affinity for CD38-expressing cells (including plasma mother cells, plasma cells, and natural killer cells), which depletes CD38-expressing tumor cells through antibody- and complement-dependent cytotoxicity Mezagitamab may be used in the study of recurrent/refractory multiple myeloma (RRMM), which is the most common form of cancer. multiple myeloma (RRMM) and primary thrombocytopenic purpura (ITP).